January 12, 2023Open Access

The RNA m6A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

YHYun‐Guang HongCentral People's Hospital of Zhanjiang ZYZhigang YangGuangdong Medical College YCYan ChenSun Yat-sen University

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The m6A reader YTHDF1 is required for progression of acute myelogenous leukemia and can be targeted with the FDA-approved drug tegaserod to suppress leukemia growth.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Hong et al. (Thu,) studied this question.

synapsesocial.com/papers/69df0c7cde200760a861427f https://doi.org/https://doi.org/10.1158/0008-5472.can-21-4249

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase.1997 · 987 citations
2Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation2019 · 58 citations
3RETRACTED: RFC2, a direct target of miR‐744, modulates the cell cycle and promotes the proliferation of CRC cells2020 · 33 citations
4ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays2009 · 2,199 citations
5Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia2020 · 20 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo